drugset / Trial / NCT02827838

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

NCT02827838

NaSingle-groupOpen-labelTreatment

Summary

This pilot clinical trial studies how well durvalumab before surgery works in treating patients with oral cavity or oropharynx cancer. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread.

Timeline

Start
2017-01
Primary completion
2022-04-22
Completion
2022-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody Intravenous